GLYCOMIRA THERAPEUTICS AWARDED $2.8M FROM THE NATIONAL INSTITUTES OF HEALTH TO ADVANCE LEAD COMPOUND TOWARDS THE CLINIC.
(Salt Lake City, UT, October 26, 2021) – GlycoMira Therapeutics announced that it received a $2.8M award from the National Institutes of Health to develop its lead compound, GM-1111, as a therapeutic for oral mucositis arising from radiation treatment of head and neck cancers. The award will enable the completion of the requisite pre-clinical studies necessary for filing an Investigational New Drug (IND) application to initiate human clinical trials.
Oral mucositis is a common, debilitating complication characterized by painful, severe ulcerations of the mouth that develop in head and neck cancer patients receiving chemoradiation therapy. The disease substantially degrades quality of life and compromises treatment and prognosis. Over 67K new head and neck cancer cases occur annually in the U.S., and the global market for the treatment of such cancers is projected to reach $2.3B by 2025.
GlycoMira’s pivotal studies in pre-clinical models demonstrate a significant reduction in the occurrence and severity of oral mucositis. Significant reductions in tumor volume were additionally observed in head and neck squamous cell carcinoma models when GM-1111 was administered as an adjuvant to radiation therapy. GM-1111 is believed to suppress tumor growth by blocking innate immune receptors and angiogenic factor-mediated cell signaling, as well as inhibiting cancer stem cell growth which is expected to improve therapeutic outcomes.
Dr. Stephen Sonis, Professor of Oral Medicine at Harvard stated, “Oral mucositis remains a common and devastating side effect of radiation therapy for head and neck cancers. Critically, it is often a reason why patients are unable to complete optimal anti-cancer treatment. I am excited to collaborate with the GlycoMira team so that we can accelerate the move of their innovative technology into the clinic.”
GlycoMira Therapeutics is a privately owned Salt Lake City based biopharmaceutical company focused on the pre-clinical development of innovative anti-inflammatory and immune-modulating therapeutics for oncology applications. The Company’s lead compound, GM-1111, is a unique synthetic glycosaminoglycan with potent anti-inflammatory and anti-cancer properties. To date, GlycoMira has received over $12M in NIH funding to support the development of GM-1111 for unmet medical needs.
GlycoMira announces Phase IIB Bridge grant award ($2M) from the NIH (NIAID) for continuing efforts to develop the company’s lead candidate drug GM-1111 as a therapeutic for chronic rhinosinusitis (CRS). This competitive award will support the completion of IND enabling studies.
(Salt Lake City, UT, June 24th, 2021) Afflicting about 28.9 million US adults (CDC data), CRS manifests debilitating clinical signs causing serious declines in quality of life yet the therapeutic options have been largely limited to nasal irrigation, steroids, and surgery. GlycoMira has been developing a nonsteroidal therapeutic solution to address this largely unmet medical need. GlycoMira’s GM-1111 is a synthetic glycosaminoglycan-based drug that inhibits pattern recognition receptors (PRRs). PRRs are part of innate immune molecules responsible for initial tissue signaling of inflammation as well as amplification of disease progression that typically occurs in various chronic inflammatory diseases.
In preclinical studies, topically applied GM-1111 significantly reduced the clinical signs of CRS. Concurrent reduction of inflammatory molecules within the tissue treated with GM-1111 suggest the therapeutic potentials in CRS patients. In addition, GM-1111 has mucolytic properties that can enhance its therapeutic effects in severe cases of CRS with cystic fibrosis (CF).
Located in Salt Lake City, GlycoMira is a development stage company that specializes in synthetic glycosaminoglycan-based technologies started from the University of Utah. GM-1111 has been developed for oncology (an anticancer drug that can also significantly reduce the adverse effects of cancer therapy) and respiratory indications (CRS and CF).